Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accumulated Expenses (2018 - 2025)

Black Diamond Therapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $15.2 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 8.54% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $15.2 million, down 8.54%, while the annual FY2025 figure was $15.2 million, 8.54% down from the prior year.
  • Accumulated Expenses reached $15.2 million in Q4 2025 per BDTX's latest filing, up from $14.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $21.5 million in Q3 2021 to a low of $14.1 million in Q1 2021.
  • Average Accumulated Expenses over 3 years is $16.6 million, with a median of $16.0 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: surged 455.08% in 2021, then dropped 22.62% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $21.5 million in 2021, then dropped by 22.96% to $16.6 million in 2024, then fell by 8.54% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Accumulated Expenses are $15.2 million (Q4 2025), $14.6 million (Q3 2025), and $16.0 million (Q2 2025).